Working extra NHS shifts to cover Mounjaro costs: what private treatment actually involves

Step 1: understand what drives the price before comparing providers

Mounjaro's licensed dosing schedule starts at 2.5mg, a lower strength whose job is to let your body adjust before the prescriber moves you up through 5mg, 7.5mg, 10mg, 12.5mg and eventually 15mg, each step requiring a clinical decision, not just an automatic refill. Because higher doses cost more to manufacture and procure, monthly spend tends to rise as treatment progresses. That's worth knowing before you budget around the lowest advertised figure, because the 2.5mg starter cost and the 15mg maintenance cost are not the same number.

Since Eli Lilly increased Mounjaro's UK list price on 1 September 2025 (with the highest-dose pen rising from around £122 to around £330 at list price) private providers have priced accordingly. Reported monthly costs now range from roughly £149 at the lower doses to around £375 at the top, though prices differ between services and change without notice. The full picture of what shapes Mounjaro's private price in the UK is worth reading before you commit to any provider.

One misconception that comes up regularly: that a very low price means a clinic has a special deal with the manufacturer. Eli Lilly sells through the licensed UK supply chain at the same list price for all regulated buyers. A price significantly below market almost always means something is missing from what's included, or from the supply chain itself.

Step 2: identify what a headline price actually includes

This is where the arithmetic gets unreliable. A quoted monthly figure might cover the medicine only, with a separate consultation fee charged upfront, a prescription-writing fee added at checkout, and delivery billed on top. Some services charge for dose-review calls; others invoice for aftercare separately. Breaking down what a Mounjaro price quote usually does and doesn't cover can save a genuine surprise when the invoice arrives.

For an NHS worker doing shift calculations, the question to ask any provider is direct: what does this price include, in total, every month? If the answer involves multiple line items, the real cost is the sum of all of them, not the headline. Consultation, prescription, medicine, delivery, and clinical aftercare are all legitimate costs of safe treatment, they just aren't always bundled.

NICE's appraisal of tirzepatide, TA1026, gives useful context on the clinical framework around which any responsible prescribing service should be operating, even in the private setting.

Step 3: weigh what that total buys, not just what it costs

At nume, we are not the cheapest option and have no intention of becoming one. What the price covers is a free consultation, a free prescription, the treatment itself, free next-working-day tracked delivery via DPD in plain packaging, and seven-day aftercare from a clinical team, with every repeat order reviewed personally before it ships. There is no subscription. There is no auto-renewal you have to remember to cancel. The approach we take at nume is built around clinical accountability at every stage, and that costs something.

For anyone in healthcare, the logic will be familiar: in clinical practice, cheapest rarely means best-value, and the same reasoning applies to treatment procurement. The right question for a prescription medicine isn't which provider charges the least, it's which service will review your case properly, dispense from a verified supply chain, and be reachable if something changes. A pharmacist's registration number is verifiable at the GPhC register; any legitimate online pharmacy should invite you to check.

NHS access: the route that doesn't require extra shifts

It's worth being clear about the NHS route, because a number of people working in the NHS don't realise they may qualify, or assume they don't. NICE recommended tirzepatide for NHS use in December 2024 (TA1026), and NHS England has been rolling out access in phases. As of June 2026, people with a BMI of 35 or above plus four or more qualifying conditions are in scope; a second cohort covering BMI 35–39.9 with four or more conditions was activated in June 2026. What Mounjaro costs on the NHS (including the prescription charge rules) is covered in detail separately.

The NHS criteria are strict and the rollout is phased; not everyone who would benefit clinically qualifies yet, and waiting times vary by area. From April 2026, GP practices can prescribe under the new contract, though participation is optional. If you want to understand how much Mounjaro is on the NHS, including how the standard prescription charge applies and when exemptions do or don't cover it, that question is covered in full on its own page, because the answer depends on the Mounjaro NHS price structure and your individual exemption status, not simply on whether you work in the health service. For anyone still weighing up whether the NHS route is financially realistic, a closer look at how much Mounjaro costs on the NHS, including where prescription charge exemptions apply and where they don't, can help clarify the numbers before you decide.

Private treatment through a GPhC-registered pharmacy is the practical alternative for people who don't currently meet NHS thresholds or can't wait. It's a clinical process either way, and eligibility is assessed by a prescriber, not decided by a price point. Exploring the treatment options available privately is a reasonable starting point if you're not yet sure which route applies to you.